Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 39 OC6.5 | DOI: 10.1530/endoabs.39.OC6.5

28 views


1Developmental Endocrinology Research Group, Royal Hospital for Sick Children, University of Glasgow, Glasgow, UK; 2Department of Biochemistry, Royal Hospital for Sick Children, Glasgow, UK; 3Paediatric Unit, Department of Medical and Surgical Sciences for Mother, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.


Objective: Prospective evaluation of the relationship between first morning urinary gonadotrophins (uGn) measured by immunoassay and corrected for creatinine (uLH:uCr and uFSH:uCr), and basal serum gonadotropins (sLH and sFSH) and in response to LHRH stimulation test. Prospective evaluation of uGn trend in patients receiving GnRH analogue (GnRH-a; decapeptyl SR, 11.25 mg, every 10–12 weeks).

Methods: Enrolled 15 (12M) patients evaluated for delayed puberty, 14 (F) for suspected precocious puberty and 16 (3M) on GnRH-a. Three first morning urine samples of three mornings before the stimulation test or before the GnRH-a injection were collected. For patients on treatment, three samples 5/6 weeks after injections were also collected. Data were expressed as median (range), and analyzed by SPSS v10.0 (P<0.05).

Results: Coefficient of variation (CV) of samples collected before the stimulation test was 0.28 (0–1.4) for uLH:uCr and 0.26 (0.05–0.99) for uFSH:uCr. Significant correlations between sLH and uLH:uCr (r=0.7; P<0.001) and between sFSH and uFSH:uCr (r=0.9; P<0.001) were identified.

Based on receiver operator characteristics analysis, a uLH:uCr value of 0.032 IU/mmol as a cut-off would detect a sLH peak >5 UI/l (sensitivity: 87%; specificity: 86%; and area under the curve: 0.89).

For patients on treatment, uLH:UCr CV of samples collected before the injection was 0.29 (0.14–0.85) and after 5/6 weeks 0.33 (0.04–0.63), while for uFSH:UCr, respectively, 0.24 (0.13–0.52) and 0.4 (0.08–1.3).

Median uLH:UCr and uFSH:UCr values before injections (0.01 and 0.34 IU/mmol) were significantly higher than after 5/6 weeks (0.008 and 0.09 IU/mmol) (P: 0.000 and P: 0.000 respectively).

Conclusion: UGn is a useful, non-invasive instrument for diagnosis and management of pubertal disorders.

Volume 39

43rd Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.